|
Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer Clinical research trials and Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer. Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer clinical trial. Subjects typically recieve the finest healthcare available for their Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer
Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer
For Condition: Non-small cell lung cancer
Status: No longer recruiting
Sponsor(s): Ligand Pharmaceuticals ,
Synopsis: Ligand Pharmaceuticals Inc. is studying the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer.
Details: Ligand Pharmaceuticals Inc. is studying the use of Targretin capsules (bexarotene) in combination with Cisplatin and Vinorelbine for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. In these studies, every patient receives a platinum-containing chemotherapy every four weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients must have: - Pathologic (histologic or cytologic) confirmation of NSCLC - Stage IIIB with malignant pleural effusion or Stage IV disease - At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy - ECOG performance status 0 or 1 - Adequate organ system function - Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy). Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months) Patients must not have had: - Brain metastasis - Prior chemotherapy for NSCLC - Prior platinum-based chemotherapy for any indication
Total Enrollment: 600
Location and Contact Information:
Overall Study Official:
MackMabry, Study Director, Ligand Pharmaceuticals
SUNY Downstate Medical Center
Brooklyn, New York, 11203
United States
VA Western New York Health Care System
Buffalo, New York, 14215
United States
7th Pneumonology Clinic, Sotiria Hospital for Diseases of the Chest
Athens, , 11527
Greece
Institut Jean Godinot
Reims, Cedex, 51100
France
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie
Krakow, , 31-115
Poland
Bay Area Cancer Consultants
Palm Harbor, Florida, 34684
United States
Hematology-Oncology Associates
Toledo, Ohio, 43623
United States
2nd Pulmonary Clinic of G. Papanikolaou Hospital
Exochi, Thessaloniki, 57010
Greece
Nemocnice odd. Onkologie
Ceske Budejovice, , 370 87
Czech Republic
Tel-Aviv Sovrasky Medical Center
Tel Aviv, , 64239
Israel
Research Institute of Oncology n.a. Hertzen
Moscow, , 12584
Russian Federation
Brookwood Medical Center
Birmingham, Alabama, 35209
United States
Northwest Medical Specialists
Arlington Heights, Illinois, 60004
United States
Port Macquarie Base Hospital
Port Macquarie, New South Wales, 2444
Australia
Burnside War Memorial Hospital
Toorak Gardens, South Australia, 5065
Australia
Tariq Mahmood
Midwest City, Oklahoma, 73110
United States
City Oncology Clinical Center
Moscow, , 107005
Russian Federation
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112
United States
Centre Hospitalier Intercommunal de la Haute-Saone
Vesoul, Cedex, 70014
France
Centre Hospitalier General de Belfort
Belfort, Cedex, 90016
France
6th Pneumonology Department, Sotiria Hospital for Diseases of the Chest
Athens, , 11527
Greece
Regionalne Centrum Onkologii
Bialystok, , 15-027
Poland
Instytut Gruzlicy i Chorob Pluc
Warsaw, , 01-138
Poland
Klinika pneumologie a hrudni chirurgie 3.LF
Praha-8, , CZ-180 00
Czech Republic
Bristol Hematology and Oncology Centre
Bristol, England, BS2 8ED
United Kingdom
Veterans Affairs Medical Center
Miami, Florida, 33125
United States
1st Pulmonary Clinic of G. Papanikolaou Hospital
Exochi, Thessaloniki, 57010
Greece
Cancer Care Manitoba
Winnepeg, Manitoba, R3E 0V9
Canada
University General Hospital of Heraklion
Heraklion, Crete,
Greece
Royal Hobart Hospital
Hobart, Tasmania, 7001
Australia
Sheba Medical Center
Tel Hashomer, , 52620
Israel
Medical Associates Health Centers
Menomonee Falls, Wisconsin, 53051
United States
Arroyo Research Inc.
Pasadena, California, 91105
United States
Chelsea & Westminster Hospital
London, England, SW10 9NH
United Kingdom
University of Florida
Gainesville, Florida, 32610
United States
City Oncology Center
St Petersburg, , 197022
Russian Federation
St. Joseph Mercy Oakland Hospital
Pontiac, Michigan, 48341
United States
Queen Elizabeth Hospital
Woodville, South Australia, 5011
Australia
University Hospital of Patras
Rio, , 26500
Greece
Canberra Hospital
Garran, Australian Capital Territory, 2605
Australia
St. Petersburg Pavlov State Medical University
St Petersburg, , 197089
Russian Federation
QEII Health Sciences Center
Halifax, Nova Scotia, B3H 1V7
Canada
Aberdeen Royal Infirmary
Foresterhill, Aberdeen, AB25 2ZN
United Kingdom
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2
Canada
Pneumologicka klinika 1. LF UK
Praha-6-Veleslavin, , CZ-160 00
Czech Republic
Assaf Harofeh Medical Center
Zerifin, , 70300
Israel
Semmelweis University Department of Pulmonology
Budapest, , 1125
Hungary
Desert Hematology-Oncology Medical Group, Inc.
Rancho Mirage, California, 92270
United States
Southern Arizona VA Healthcare System
Tucson, Arizona, 85723
United States
Border Medical Oncology
Wodonga, Victoria, 3690
Australia
Russian Oncology Research Center n.a. Blokhin
Moscow, , 115478
Russian Federation
Marshfield Medical Research Foundation
Marshfield, Wisconsin, 54449
United States
Ottawa Regional Cancer Centre
Ottawa, Ontario, K1H 1C4
Canada
Koranyi National Institute for Pulmonology
Budapest, , 1529
Hungary
Kaplan Medical Center
Rehovot, , 76100
Israel
Capitol Comprehensive Cancer Care Clinic
Jefferson City, Missouri, 65109
United States
City Oncology Hospital #62
Moscow, , 143423
Russian Federation
Jayne Gurtler, M.D., APMC
Metairie, Louisiana, 70006
United States
Arkhangelsk Regional Oncology Center
Arkhangelsk, , 163045
Russian Federation
Box Hill Hospital
Box Hill, Victoria, 3128
Australia
Hadassah Medical Center
Jerusalem, , 19200
Israel
Research Institute of Oncology n.a. Petrov
St Petersburg, , 197758
Russian Federation
Csongrad Megyei Onkormanyzat Mellkasi
Deszk, , 6772
Hungary
Barzilai Medical Centre
Ashkelon, , 78308
Israel
Southern Medical Daycare Centre
Wollongong, New South Wales, 2500
Australia
Fovarosi Onkormanyzat Uzsoki utcai, Korhaza
Budapest, , 1145
Hungary
Meir Hospital
Kfar Sava, , 44281
Israel
New Hope Cancer Center
Hudson, Florida, 34667
United States
University Hospital of Alexandroupolis
Dragana, Alexandroupolis, 68100
Greece
University Oncology & Hematology Associates
Chattanooga, Tennessee, 37404
United States
Centre Hospitalier Francois Maillot
Briey, Cedex, 54150
France
Wielkopolskie Centrum Chorob Pluc I Gruzlicy
Poznan, , 66-569
Poland
Central Clinical Hospital n.a. Semashko
Moscow, , 129128
Russian Federation
Akademii Medycznej w Gdansku
Gdansk, , 80-216
Poland
Leicester Royal Infirmary
Leicester, England, LE1 5WW
United Kingdom
Guys & St. Thomas' Cancer Centre
London, England, SE1 9RT
United Kingdom
University of Edinburgh
Edinburgh, Scotland, EH4 2XU
United Kingdom
Additional Information:
Study ID Numbers: L1069-49;
Study Start Date:
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050973
Other Non-Small Cell Lung Cancer Studies:
1. TLK286 and Docetaxel in Treating Patients With Stage IIIB or Stage IV Platinum-Resistant Non-Small Cell Lung Cancer
2. Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients with Advanced Non-Small Cell Lung Cancer
3. Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
4. Iressa/Docetaxel in Non-Small-Cell Lung Cancer
5. Isotretinoin With or Without Vitamin E for Prevention of Lung Cancer
Related Studies:
Other Non-small cell lung cancer Clinical Trials
Other Clinical Trials
Other Zerifin Clinical Trials
Evaluation of efficacy, safety and tolerability of Targretin capsules in patients with advanced or metastatic non-small cell lung cancer
|
|
|
|
|
|
|
|